New drug combo targets Tough-to-Treat bone marrow cancer
NCT ID NCT07387354
First seen Feb 04, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tests a combination of two drugs, pacritinib and azacitidine, in 25 people with myelodysplastic syndrome (MDS) at moderate to very high risk. The first part finds the safest dose of pacritinib, and the second part checks how well the combo works. Researchers will also look at blood samples to see how the drugs affect cell signals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.